Latest Filings

Issuer Activity

Insider Overview :: Acasti Pharma Inc. (V:APO) [?]
Business Focus: Pharmaceuticals
Recent Price for APO
CAD 2.68 0.00 (0.00%)
TSXV Delayed 15 minutes
May 23 1539 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 2.76 0.0 N/A 196.10
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 1.60 0.0% 13,785  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 23rd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 29/13 Apr 26/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -4,200 $2.25
Apr 29/13 Apr 24/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -22,500 $2.32
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.26
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.27
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.28
Apr 23/13 Apr 18/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -300 $2.30
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 54 - Exercise of warrants 22,500 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Warrants (Séries 4) 54 - Exercise of warrants -22,500 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 51 - Exercise of options 3,750 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Options 51 - Exercise of options -3,750 $0.250
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 23rd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Apr 29/13 Apr 26/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -4,200 $2.25
Apr 29/13 Apr 24/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -22,500 $2.32
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.26
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.27
Apr 23/13 Apr 19/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,000 $2.28
Apr 23/13 Apr 18/13 Massrieh, Wael Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -300 $2.30
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 54 - Exercise of warrants 22,500 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Warrants (Séries 4) 54 - Exercise of warrants -22,500 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Common Shares (Actions de catégorie A) 51 - Exercise of options 3,750 $0.250
Apr 13/13 Apr 8/13 Chartrand, Michel Direct Ownership Options 51 - Exercise of options -3,750 $0.250
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for APO on May 23, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
Ronald Denis
Independent Chairman of the Board 		Tina Sampalis
President 		Henri Harland
Chief Executive Officer, Director
Henri Harland
Chief Executive Officer, Director 		Xavier Harland
Chief Financial Officer 		Xavier Harland
Chief Financial Officer
Pierre Lemieux
Chief Operating Officer 		Harlan W. Waksal
Executive Vice President - Business and Scientific Affairs 		 
Company Contact
Address: 225 Promenade du Centropolis
LAVAL QC H7T 0B3
Tel: --
Website: www.acastipharma.com
IR: See website
Business Overview
Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.
Competitors with Recent Insider Filings
Paladin Labs (T:PLB)
Sophiris Bio (T:SHS)
Cipher Pharmaceuticals (T:DND)
 
Acasti Pharma Inc. Insider Report Only $20.00